John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A, Torres E, Papadakis G, Rizzoli R, Cooper C, Pearson G, Boonen A. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford). 2017 Jul 1;56(7):1167-76. doi: 10.1093/rheumatology/kex071
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Hifinger M, Hiligsmann M, Ramiro S, Severens JL, Fautrel B, Watson V, Boonen A. Patient's preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. Rheumatology (Oxford). 2017 Jan;56(1):68-76. doi: 10.1093/rheumatology/kew328
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Capdevila Bert R, Marsal Mora JR, Pujol Salud J, Anguera Farran R. Prevalence study of iodine deficiency in a 6-year-old school population. An Pediatr (Barc). 2010 May;72(5):331-8. doi: 10.1016/j.anpedi.2009.12.023
Keenan A-M, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQoL: development and preliminary validation of a needs-based quality of life measure for osteoarthritis. Poster presented at the American College of Rheumatology 2007 Annual Scientific Meeting; April 2007. Chicago, IL. [abstract] Rheumatology (Oxford). 2007; 46:162-3.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.